Study rating attractiveness of women with endometriosis is not yet retracted

Despite media reports announcing the retraction of a much-criticized study of whether women with endometriosis were more attractive than other women, the study has yet to be retracted by the journal.

Last week, several news outlets, picking up on a story in The Guardian, said the study, first published in 2012 in Fertility and Sterility, had been retracted. 

The study, called “Attractiveness of women with rectovaginal endometriosis: a case-control study,” claimed to show that:

Continue reading Study rating attractiveness of women with endometriosis is not yet retracted

A retraction and a retraction request as Twitter users call out sexism, fat-shaming, and racism

Overweight people are more dishonest, women with endometriosis are more attractive, and affirmative action needs to stop: Papers with these three conclusions have come under intense scrutiny on social media in recent days, with at least one retracted. 

First up, a study — widely criticized for being sexist — which claimed to find that

Women with rectovaginal endometriosis were judged to be more attractive than those in the two control groups. Moreover, they had a leaner silhouette, larger breasts, and an earlier coitarche.

The study, called “Attractiveness of women with rectovaginal endometriosis: a case-control study” was published in 2013 in Fertility and Sterility, an Elsevier publication. It received sharp criticism on PubPeer beginning a year ago when one commenter, “Ovine Mastadenovirus,” wrote:

Continue reading A retraction and a retraction request as Twitter users call out sexism, fat-shaming, and racism

Cancer surgery group in China may lose second paper

After whistleblowers in China prompted the retraction of a 2018 paper that overstated the number of patients treated in a study, another journal says it’s investigating a second article by the same group.

Last month, as we reported, the Journal of Surgical Oncology retracted “Long‐term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy.” The move was prompted by whistleblowers who notified the journal that the 530 cases could not have been performed at the authors’ institution, Zhejiang University, in Hangzhou. 

After our post, a Twitter user pointed us to a second article by the group, in BMC Cancer, which claimed to report data on 697 subjects over just one additional year — a highly improbable figure. 

Continue reading Cancer surgery group in China may lose second paper

A bitter aftertaste: Legal threats, alleged poisoning muddy the waters for a trial of a tea to treat malaria

Artemisia afra, via Wikimedia

Xavier Argemi first heard the claim that tea made from artemisia herbs could be useful in the treatment of malaria from a TV documentary in 2017.

The documentary, featuring Lucile Cornet-Vernet, the director of the La Maison de l’Artemisia, a non-profit organization that grows artemisia and promotes its use in centers across Africa, focused on the Democratic Republic of the Congo (DRC). The film claimed that for decades major pharmaceutical companies have been profiting from expensive malaria drugs based on artemisinin — the antimalarial for which Tu Youyou won a Nobel Prize in 2015, after distilling it from the Artemisia annua plant — while the tea itself, an ancient Chinese herbal remedy, was just as effective at treating the disease.

His interest piqued, Argemi reached out to Cornet-Vernet, an orthodontist at Paris’ Descartes University. She shared with him the unpublished manuscript of a study — their first large-scale clinical trial — which she said showed that artemisia outperformed a go-to treatment for schistosomiasis, a different parasite-induced disease.

Argemi immediately saw red flags. “I am not a specialist of malaria or schistosomiasis, but when I read the study I was simply totally surprised by the number of inconsistencies at the very first read,” Argemi, of the Clinique Axium in Strasbourg, France, told Retraction Watch by email. 

Continue reading A bitter aftertaste: Legal threats, alleged poisoning muddy the waters for a trial of a tea to treat malaria

USC-Children’s Hospital Los Angeles researcher out following misconduct probe

Prasadarao Nemani

An infectious diseases researcher found by a federal U.S. watchdog to have “recklessly” faked data in grants worth millions left his job as the investigation was coming to a close, Retraction Watch has learned.

As we reported last week, Prasadarao Nemani, of Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC), “engaged in research misconduct by recklessly including falsified and/or fabricated data” in a 2009 paperretracted in 2018 — and four NIH grant applications, according to the U.S. Office of Research Integrity.

Earlier this week, in a statement provided to Retraction Watch, CHLA said that he was no longer with the hospital or with USC:

Continue reading USC-Children’s Hospital Los Angeles researcher out following misconduct probe

‘Some papers can slip through the net,’ says journal that published 5G-COVID-19 paper

We have heard back this morning from the publisher of a journal that yanked a paper that linked 5G cellphone technology and the novel coronavirus last week — a paper that scientific sleuth Elisabeth Bik mused was the “worst paper of 2020.”

The response to our request for comment from editor in chief Pio Conti reads a bit like a Mad Libs of excuses we hear from publishers when something goes wrong. Read carefully for:

Continue reading ‘Some papers can slip through the net,’ says journal that published 5G-COVID-19 paper

Blaming “overflow of manuscripts” and “obviously biased” reviewers, journal will retract homeopathy-COVID-19 paper

A public health journal will be retracting a paper that argued for the adoption of homeopathy in the fight against the coronavirus pandemic, according to the editor in chief.

We reported on Saturday that the Journal of Public Health: From Theory to Practice, a Springer Nature title also known by its German name, Zeitschrift für Gesundheitswissenschaften, had published “Homeopathy combat against coronavirus disease (Covid-19)” on June 5.

At the time, we had not yet heard from Joachim Kugler, the journal’s editor, about how this might have happened. Today, Kugler told Retraction Watch:

Continue reading Blaming “overflow of manuscripts” and “obviously biased” reviewers, journal will retract homeopathy-COVID-19 paper

Paper blaming COVID-19 on 5G technology withdrawn

via Pixabay

A paper which argued that 5G cellphone technology could lead to infection with the novel coronavirus has been retracted, but not before scientific sleuth Elisabeth Bik wondered whether it was the “worst paper of 2020.”

The article, “5G Technology and induction of coronavirus in skin cells,” came from a group from Italy, the United States and Russia, and appeared in the Journal of Biological Regulators and Homeostatic Agents. The journal is published by Biolife, which asserts that it’s peer reviewed but has not responded to a request for comment. [Please see an update on this post.]

The abstract is now marked “WITHDRAWN” on PubMed and the paper has disappeared from the journal’s website. The abstract has been preserved here. According to the authors: 

Continue reading Paper blaming COVID-19 on 5G technology withdrawn

Paper urging use of homeopathy for COVID-19 appears in peer-reviewed public health journal

A peer-reviewed journal has published a paper that urges the adoption of homeopathy in the fight against the coronavirus pandemic.

[Please see an update on this post.]

The Journal of Public Health: From Theory to Practice — published by Springer Nature and also known by its German name, Zeitschrift für Gesundheitswissenschaften — published “Homeopathy combat against coronavirus disease (Covid-19)” on June 5. It is indexed in PubMed Central, although not on Medline.

Here’s the abstract:

Continue reading Paper urging use of homeopathy for COVID-19 appears in peer-reviewed public health journal

Journal to retract paper that spawned #medbikini

From the Journal of Vascular Surgery paper

The Journal of Vascular Surgery says it will retract a paper about surgeons’ social media posts that said health care professionals who posted pictures of themselves in bikinis were engaging in “potentially unprofessional” behavior — and led to a firestorm on Twitter yesterday.

As Medscape reported yesterday before the retraction:

Medical professionals are tweeting pictures of themselves in swimsuits with the hashtag #MedBikini, accompanied by sharp rebukes of a study that labeled such images on social media as “potentially unprofessional.” 

Continue reading Journal to retract paper that spawned #medbikini